Certara, Inc. (NASDAQ: CERT) corrects 2025 EBITDA for divested unit
Rhea-AI Filing Summary
Certara, Inc. clarified financial information related to its recently divested Regulatory and Medical Writing business that had been discussed on its second quarter 2026 earnings conference call and in the accompanying presentation. Management had described the business as having generated approximately $17 million of adjusted EBITDA in 2025 “excluding unallocated overhead costs,” which was incorrect.
The company states that the approximately $17 million of adjusted EBITDA for 2025 is calculated including unallocated overhead costs. On an alternative basis that excludes unallocated corporate expense that will remain with Certara, the business generated approximately $23 million of adjusted EBITDA in 2025. Certara indicates that this clarification does not affect any previously reported financial results, year-over-year comparisons, or its 2026 financial outlook.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 7.01 — Regulation FD Disclosure
1 item
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Key Figures
2025 adjusted EBITDA including unallocated overhead: approximately $17 million
2025 adjusted EBITDA excluding unallocated corporate expense: approximately $23 million
Common stock par value: $0.01 per share
3 metrics
2025 adjusted EBITDA including unallocated overhead
approximately $17 million
Adjusted EBITDA in 2025 for the divested Regulatory and Medical Writing business including unallocated overhead costs
2025 adjusted EBITDA excluding unallocated corporate expense
approximately $23 million
Adjusted EBITDA in 2025 for the Regulatory and Medical Writing business excluding unallocated corporate expense that will remain with Certara
Common stock par value
$0.01 per share
Par value of Certara, Inc. common stock as listed in the registration table
Key Terms
Regulation FD Disclosure, adjusted EBITDA, unallocated corporate expense, earnings conference call
4 terms
Regulation FD Disclosure regulatory
"Item 7.01 Regulation FD Disclosure."
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
adjusted EBITDA financial
"generated approximately $17 million of adjusted EBITDA in 2025"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
unallocated corporate expense financial
"excluding unallocated corporate expense that will remain with the Company"
earnings conference call financial
"hosted its second quarter 2026 earnings conference call"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What clarification did Certara (CERT) provide about its 2025 adjusted EBITDA?
Certara clarified that its divested Regulatory and Medical Writing business generated approximately $17 million of adjusted EBITDA in 2025 including unallocated overhead costs. Earlier, this same $17 million figure was mistakenly described as excluding unallocated overhead on the Q2 2026 earnings call and in the related presentation.
What is the 2025 adjusted EBITDA for Certara's divested unit excluding certain corporate expenses?
Certara reports that the divested Regulatory and Medical Writing business generated approximately $23 million of adjusted EBITDA in 2025 excluding unallocated corporate expense that will remain with the company. This provides an additional view of the business’s performance separate from overhead that stays with Certara.
Does Certara's clarification affect previously reported CERT financial results?
Certara states that the clarification has no impact on previously reported financial results. The change corrects how the 2025 adjusted EBITDA of the divested Regulatory and Medical Writing business was described, without altering historical financial statements or year-over-year comparisons.
Does the corrected EBITDA disclosure change Certara's 2026 financial outlook?
No. Certara explicitly notes that the clarification has no impact on its 2026 Financial Outlook. The adjustment relates only to wording around the 2025 adjusted EBITDA of the divested Regulatory and Medical Writing business, rather than to current-year guidance figures.
Which Certara business is affected by the corrected 2025 EBITDA figure?
The clarification concerns Certara’s recently divested Regulatory and Medical Writing business. The company corrected its description of that unit’s 2025 adjusted EBITDA on the Q2 2026 earnings call and updated the related earnings presentation posted on its investor relations website.